Pre-transplant cytoreductive therapy can improve overall survival of patients with MDS-AML but not MDS-EB2 receiving HLA-matched sibling donor peripheral blood stem cell transplantation

To evaluate whether cytoreductive therapy is needed for myelodysplastic syndromes (MDS) patients with excess blasts type 2 (MDS-EB2) and acute myeloid leukemia derived from MDS (MDS-AML) before HLA-matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT), we retrospectively analy...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Am J Cancer Res
Päätekijät: Wang, Qianqian, Zhao, Xingli, Liu, Zixian, Zhao, Xiaoli, Zhang, Guixin, Yao, Jianfeng, Zheng, Xiaohui, Zhang, Lining, Shen, Yuyan, He, Yi, Huang, Yong, Zhang, Rongli, Wei, Jialin, Ma, Qiaoling, Pang, Aiming, Yang, Donglin, Jiang, Erlie, Feng, Sizhou, Zhang, Zhuoran, Zhai, Weihua, Han, Mingzhe
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: e-Century Publishing Corporation 2020
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7191098/
https://ncbi.nlm.nih.gov/pubmed/32368397
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia